



RECEIVED

NOV 26 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1632

Hallenbeck, *et al.*

Examiner: J. Woitach

APPLICATION NO: 09/373,938

Atty. Docket: 4-30899P1

FILED: August 13, 1999

Confirmation No. 3124

FOR: ADENOVIRAL VECTORS INCLUDING DNA SEQUENCES
ENCODING ANGIOGENIC INHIBITORS

Commissioner for Patents
Washington, D.C. 20231-0001
ATTN: BOX AF

TRANSMITTAL LETTER


Sir:

Enclosed please find the following, which is being hand delivered to the U.S. Patent and Trademark Office on November 22, 2002:

- a) Reply After Final Under 37 C.F.R. §1.116, with Exhibits 1 and 2 attached;
- b) Diskette containing Sequence Listing and corresponding paper copy of sequence listing;
- c) Twenty (20) sheets of formal drawings with copy of Notice of Draftperson's Patent Drawing Review attached;
- d) Declaration of Prior Invention Under 37 C.F.R. §1.131 with Exhibits A, B, and C attached;
- e) Notice of Appeal from the Examiner to the Board of Patent Appeals and Interferences;
- f) Fee Transmittal sheet; and
- g) Postcard receipt.

The Commissioner is hereby authorized to charge any fees that may be required by this transmittal letter, or to credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,



J. Timothy Meigs
Attorney for Applicants
Reg. No. 38,241
(301) 258-4715

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: November 22, 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

Complete if Known

Application Number	09/373,938
Filing Date	08/13/1999
First Named Inventor	Hallenbeck
Examiner Name	J. Woitach
Group Art Unit	1632
Attorney Docket No.	4-30899P1

TOTAL AMOUNT OF PAYMENT (\$) 1240.00

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number: 19-0134
 Deposit Account Name: Novartis Corporation

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
106 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 160	214 80	Provisional filing fee	

SUBTOTAL (1) (\$)

2. EXTRA CLAIM FEES

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	
Multiple Dependent	-3** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 84	209 42	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	920.00
118 1,440	218 720	Extension for reply within fourth month	
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	320.00
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 1240.00)

SUBMITTED BY

Name (Print/Type)	J. Timothy Meigs	Registration No. (Attorney/Agent)	38,241	Telephone	301-258-4715
Signature	<i>J. Timothy Meigs</i>	Date	11/22/2002		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.